

7<sup>th</sup> February 2025

**Cambridge Cognition Holdings plc**  
("Cambridge Cognition" or the "Company")

**Board appointment**

Cambridge Cognition Holdings plc (AIM: COG), the brain health software group specialising in digital products that advance brain health research and treatment, is pleased to announce the appointment of Jonathan ("Jon") Kempster as an independent Non-Executive Director of the Company, with immediate effect.

Jon has more than 20 years' experience as a public company director and is currently a Non-Executive Director of three AIM quoted companies: Norman Broadbent plc, a leading Executive Search and Interim Management firm, Synthetics plc, a leader in advanced security and surveillance systems, and Pennant International Group plc, a systems support and training solutions company.

Jon qualified as a chartered accountant with Price Waterhouse in 1990 and has been CFO of a number of companies including FII Group plc, Linden Homes, Delta plc, and Frasers Group. He has held several non-executive roles since 2019.

This appointment further strengthens the Board by adding additional investor relations and financial expertise and, in taking the number of non-executive directors to six, provides strengthened governance and ensuring robust succession planning for possible future rotation of Board members.

**Dr Steven Powell, Chairman of Cambridge Cognition, commented:**

*"On behalf of the Board, I am delighted to welcome Jon to Cambridge Cognition. His broad experience and deep financial expertise will be a valuable addition to the Company as we continue to build and grow the business."*

**Further information:**

The following additional information is provided in accordance with Rule 17 and Schedule Two Paragraph (g) of the AIM Rules for Companies:

Jonathan (Jon) Kempster, aged 62, holds or has held the following directorships in the last five years:

Current directorships	Past directorships within the last five years
Norman Broadbent plc	DX (Group) Limited
Pennant International Group plc	Bonhill Group plc
Synectics plc	Independent Trustee Services Limited
JVM AG	Ted Baker Holdings Limited
JVM Property AG	Redcentric plc
Rochester Associates Ltd	FireAngel Safety Technology Group plc
Delta Pension Nominees Limited	FireAngel Safety Technology Limited
	Portcentric Solutions Limited
	Serinus Energy plc
	Prosper Solutions OU

Jonathan Kempster does not have any interest in any ordinary shares of the Company.

Save for the information disclosed above, there is no other information in relation to Jonathan Kempster that is required to be disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

**Enquiries:**

**Cambridge Cognition Holdings plc**  
Rob Baker, Chief Operating Officer and Joint Managing Director

**Tel: 012 2381 0700**

**Panmure Liberum Limited (NOMAD and Joint Broker)**  
Will Goode / Freddy Crossley / Mark Rogers  
Rupert Dearden

**Tel: 020 7886 2968**  
**(Corporate Broking)**  
**(Corporate Broking)**

**Dowgate Capital Limited (Joint Broker)**  
David Poutney / James Serjeant

**Tel: 020 3903 7715**

**Hudson Sandler (Financial PR and IR)**  
Dan de Belder / Hattie Dreyfus / Harry Griffiths

**Tel: 020 7796 4133**  
**cog@hudsonsandler.com**

**Notes to Editors**

**About Cambridge Cognition**

Cambridge Cognition is a brain health software group specializing in digital health products that advance brain health research and treatment. The company offers four core products: CANTAB® assessments-providing scientifically validated, highly sensitive, precise, and objective measures of cognitive function correlated to neural networks; a flexible and proven eCOA platform with an extensive library of instruments, enabling efficient study setup and scalable data capture; rater training services that standardise assessment delivery and scoring across clinical trials and quality assurance tools that ensure data integrity by automatically detecting deviations in administration and scoring, saving time and money. These products collectively improve clinical trial outcomes, enable early patient identification, and enhance global efficiency in healthcare and pharmaceuticals.

For further information, visit: [www.cambridgecognition.com](http://www.cambridgecognition.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@seg.com](mailto:rs@seg.com) or visit [www.rs.com](http://www.rs.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAKZGGZKVVGKZM